Allarity Therapeutics (NASDAQ:ALLR) Stock Price Down 4.6%

Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Rating)’s stock price dropped 4.6% during trading on Wednesday . The company traded as low as $0.22 and last traded at $0.22. Approximately 1,138,056 shares changed hands during mid-day trading, a decline of 7% from the average daily volume of 1,222,713 shares. The stock had previously closed at $0.23.

Allarity Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.73, a current ratio of 0.47 and a quick ratio of 0.47. The stock’s 50-day moving average is $0.35 and its 200 day moving average is $0.82.

Allarity Therapeutics (NASDAQ:ALLR – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.42). On average, sell-side analysts anticipate that Allarity Therapeutics, Inc. will post -2.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Allarity Therapeutics

A hedge fund recently bought a new stake in Allarity Therapeutics stock. Renaissance Technologies LLC purchased a new stake in shares of Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Rating) in the first quarter, according to its most recent filing with the SEC. The firm purchased 114,227 shares of the company’s stock, valued at approximately $233,000. 1.61% of the stock is owned by hedge funds and other institutional investors.

About Allarity Therapeutics

(Get Rating)

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.